GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (FRA:0PQ) » Definitions » Debt-to-Revenue

ProQR Therapeutics NV (FRA:0PQ) Debt-to-Revenue : 1.13 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

ProQR Therapeutics NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €5.90 Mil. ProQR Therapeutics NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €11.50 Mil. ProQR Therapeutics NV's annualized Revenue for the quarter that ended in Sep. 2024 was €15.37 Mil. ProQR Therapeutics NV's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 1.13.


ProQR Therapeutics NV Debt-to-Revenue Historical Data

The historical data trend for ProQR Therapeutics NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Debt-to-Revenue Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A 45.22 6.11 3.03

ProQR Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.88 1.50 1.08 0.76 1.13

Competitive Comparison of ProQR Therapeutics NV's Debt-to-Revenue

For the Biotechnology subindustry, ProQR Therapeutics NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Debt-to-Revenue falls into.



ProQR Therapeutics NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

ProQR Therapeutics NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.614 + 18.12) / 6.514
=3.03

ProQR Therapeutics NV's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.896 + 11.501) / 15.372
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


ProQR Therapeutics NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics NV Headlines

No Headlines